DocGo shares fell sharply in pre-market trading on Tuesday after the mobile healthcare and medical transportation provider reported weaker-than-expected second-quarter 2026 results and significantly increased its projected full-year adjusted EBITDA loss. The stock dropped 12.7% to $0.62 before the opening bell after DocGo posted an adjusted loss of $0.16 per share, compared with the consensus estimate for a $0.10 loss, while quarterly revenue reached $73.4 million, below analysts' forecast of $75.4 million and down 8.7% from the same period last year. The company now expects an adjusted EBITDA loss of between $17 million and $22 million for 2026, considerably wider than its previous forecast for a loss of between $5 million and $10 million. DocGo also announced a definitive agreement to acquire Hicuity Health, a telemedicine provider generating approximately $65 million in trailing 12-month revenue, and disclosed that it had requested a brief extension from the U.S. Securities and Exchange Commission to file its quarterly Form 10-Q. The sell-off occurred against a broadly negative market environment, with the Nasdaq down 1.1% and the S&P 500 falling 0.4% during Tuesday's session.
DocGo IncEarnings miss and wider adjusted EBITDA loss forecast for 2026
Acquisition by DocGo announced, but terms and impact not detailed
